Karen Vertessen

Karen Vertessen is a Visiting Fellow in the Faculty of Behavioural and Movement Sciences at Vrije Universiteit Amsterdam, specializing in Clinical Neuropsychology. She is affiliated with the IBBA (Institute for Brain and Behavior Amsterdam) and maintains an active research profile focused on ADHD treatment in children and adolescents. Her academic work bridges clinical practice with scientific research, contributing to evidence-based approaches in pediatric neuropsychopharmacology.

Dr. Vertessen's research interests center on clinical neuropsychology with a specific focus on Attention Deficit Hyperactivity Disorder (ADHD) and its pharmacological management. Her work investigates methylphenidate treatment protocols, placebo effects in ADHD medication, and optimizing titration methods for improved patient outcomes. She employs rigorous clinical trial methodologies to evaluate treatment efficacy and adherence in pediatric populations, with particular attention to individualized treatment approaches and neurocognitive outcomes. Her research spans both theoretical and practical applications, addressing real-world challenges in ADHD management.

Analysis of her recent publications reveals a strong emphasis on evidence-based ADHD treatment protocols, with particular focus on methylphenidate dosing strategies and placebo-controlled methodologies. Vertessen's research consistently examines the complex relationship between medication dosage, treatment response, and placebo effects in children with ADHD. Her work demonstrates methodological rigor through randomized controlled trials and double-blind studies, contributing significantly to understanding optimal titration practices. She has published in high-impact journals including European Child & Adolescent Psychiatry, Pediatric Drugs, and The Lancet Psychiatry, indicating recognition within the scientific community.

Vertessen actively collaborates with researchers across multiple institutions, as evidenced by her co-authorship with experts like Jan Oosterlaan, Marjolein Luman, and James M. Swanson. Her research contributes to Sustainable Development Goals related to good health and well-being, particularly in advancing child mental health care. The fingerprint analysis of her work shows strong concentration in ADHD (100%), Attention Deficit Disorder (80%), Meta-Analysis (60%), Methylphenidate research (60%), Placebo effects (40%), Titrimetry (30%), Neurocognitive Function (22%), and Rating Scale methodologies (20%).